BioCentury
ARTICLE | Finance

Found in translation

Venture backing and infrastructure give Europe's biotech sector a chance to grow

May 19, 2016 7:00 AM UTC

With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities alike to tap into the translational science stemming from its research organizations.

The bulk of that sum comes from U.K.-based funds, reflecting a recent push by the U.K. government, investors and academics to advance the country's biotech ecosystem by promoting the commercialization of its breakthrough research (see Cover Story). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article